Diabetes Drugs

Front 1

metformin

Back 1

glucophage

Front 2

metformin dose

Back 2

start 500mg BID or 850mg qd
MAX 2550mg
take with food
NO ETOH

Front 3

side effects metformin

Back 3

metallic taste
lactic acidosis (hyperventilation, malaise abd discomfort)

Front 4

metformin CI

Back 4

scr men>1.5 women >1.4

Front 5

monitor metformin

Back 5

scr/bun

Front 6

metformin ER dose

Back 6

start 500mg qd
Max 2000mg-2500mg depending on brand
take with evening meal

Front 7

sulfonylureas moa

Back 7

interact with ATP K channels in the beta cell to increase secretion of insulin

Front 8

biguanides moa

Back 8

decrease hepatic glucose output and increase peripheral glucose utilization and decrease intestinal absoprtion of glucose

Front 9

glimepride

Back 9

amayrl

Front 10

glimepride dose

Back 10

1-4mg qd
MAX 8mg

Front 11

PK glimepride

Back 11

crcl <22 use 1 mg for initial dose

Front 12

sulfonylurea ADR

Back 12

hypoglycemia
weight gain

Front 13

CI sulfonylurea

Back 13

sulfa allergy
DKA

Front 14

glipizide

Back 14

glucotrol

Front 15

glipizide dose

Back 15

start 5mg qd
max 40mg qd-- food delays absorption

Front 16

glipizide XL dose

Back 16

5-20mg
MAX 20mg
take with food

Front 17

glyburide

Back 17

diabeta, Micronase

Front 18

glyburide dose

Back 18

5-20mg qd or divided
MAX 20mg/d

Front 19

Glipizde PK

Back 19

avoid in crcl <10
no active metabolite

Front 20

glyburide PK

Back 20

avoid in crcl<50
has active metabolite

Front 21

non-sulfonylurea secretagogues MOA

Back 21

also binds to ATP-sensitive K channels in beta cell to increase secretion of insulin GLUCOSE dependent secretion of insulin

Front 22

non-sulfonylurea secretagogues agents

Back 22

Nateglinde Repaglindine

Front 23

Netaglinde

Back 23

starlix

Front 24

nateglinde dose

Back 24

60-120mg PO TID 30min AC meals
MAX 360mg
if meals skipped -- skip dose

Front 25

non-sulfonylurea secretagogues ADR

Back 25

hypoglycemia
weight gain

Front 26

netaglinde PK

Back 26

hepatic metabolite to active metabolite that is reanlly cleared

Front 27

non - sulfonylurea secretagogues CI

Back 27

DKA
type 1 DM

Front 28

repaglinide

Back 28

prandin

Front 29

repaglinide dose

Back 29

1-4mg po tid 30min ac meals
MAX 16mg
if meal skip skip dose

Front 30

repaglinide pk

Back 30

hep metabolite but at crcl <40 initiate at 0.5mg

Front 31

TZD MOA

Back 31

PPAR y increase insulin sensitivity of adipose tissue, skeletal muscle and the liver also increases HDL and decreases TG and improve endothial dysfunction

Front 32

pioglitazone

Back 32

actos

Front 33

pioglitazone dose

Back 33

15-45mg daily
MAX 45mg

Front 34

TZD onset of action

Back 34

may take 6-14 weeks to achieve max effects

Front 35

TZD ADR

Back 35

weight gain
fluid retention
peripheral edema
increase SQ adiposity
hepatoxicity
CHF/MI pulm edema

Front 36

TZD CI

Back 36

ALT>2.5x ULN
NYHA class III IV

Front 37

TZD monitoring

Back 37

ALT
lipids

Front 38

rosiglitazone

Back 38

avandia

Front 39

rosiglitazone dose

Back 39

4-8mg qd or divided
MAX 8mg/d
4mg/d with insulin

Front 40

a glucosidase inhibitors MOA

Back 40

inhibit the alpha glucosidase enzyme that lines the small intestinge interfering with hydrolysis of carbs and delaying glucose absorption and other monosaccharides

Front 41

a glucosidase inhibitors agents

Back 41

acarbose miglitol

Front 42

acarbose

Back 42

precose

Front 43

acarbose dose

Back 43

50-100mg PO TID with first bite of each meal
MAX <60kg 150mg/d
>60kg 300mg/d

Front 44

a glucosidase inhibitors PK

Back 44

no systemic absorption eliminated via fecal and renal route

Front 45

a glucosidase inhibtiors ADR

Back 45

GI abd pain diarrhea gas
moderate increase LFT
fatal hepatic failure